- Home
- PMCB vs YHC Comparison
PMCB vs YHC Comparison
Compare PMCB & YHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- YHC
- Stock Information
- Founded
- PMCB 1996
- YHC 2021
- Country
- PMCB United States
- YHC United States
- Employees
- PMCB N/A
- YHC N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- YHC Beverages (Production/Distribution)
- Sector
- PMCB Health Care
- YHC Consumer Staples
- Exchange
- PMCB Nasdaq
- YHC Nasdaq
- Market Cap
- PMCB 11.4M
- YHC 12.3M
- IPO Year
- PMCB N/A
- YHC N/A
- Fundamental
- Price
- PMCB $1.78
- YHC $1.96
- Analyst Decision
- PMCB
- YHC Strong Buy
- Analyst Count
- PMCB 0
- YHC 2
- Target Price
- PMCB N/A
- YHC $5.00
- AVG Volume (30 Days)
- PMCB 27.8K
- YHC 436.2K
- Earning Date
- PMCB 03-17-2025
- YHC 03-31-2025
- Dividend Yield
- PMCB N/A
- YHC N/A
- EPS Growth
- PMCB N/A
- YHC N/A
- EPS
- PMCB 0.74
- YHC N/A
- Revenue
- PMCB N/A
- YHC $2,272,001.00
- Revenue This Year
- PMCB N/A
- YHC $120.06
- Revenue Next Year
- PMCB N/A
- YHC $72.42
- P/E Ratio
- PMCB $2.40
- YHC N/A
- Revenue Growth
- PMCB N/A
- YHC 158.05
- 52 Week Low
- PMCB $1.39
- YHC $0.40
- 52 Week High
- PMCB $2.58
- YHC $2.16
- Technical
- Relative Strength Index (RSI)
- PMCB 56.75
- YHC N/A
- Support Level
- PMCB $1.57
- YHC N/A
- Resistance Level
- PMCB $1.80
- YHC N/A
- Average True Range (ATR)
- PMCB 0.13
- YHC 0.00
- MACD
- PMCB 0.01
- YHC 0.00
- Stochastic Oscillator
- PMCB 64.10
- YHC 0.00
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.